CA-IKOTEK
29.9.2022 15:01:38 CEST | Business Wire | Press release
Ikotek, the leading IoT original design manufacturer (ODM) and electronics manufacturing service (EMS) provider, is announcing expansion of its executive management team with industry veterans and continue their aggressive growth plans for the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005870/en/
Ikotek - Your Trusted IoT ODM Partner (Photo: Business Wire)
Headquartered in San Diego, USA, Ikotek offers a one-stop-shop for IoT solutions across design and development, hardware build, testing and verification, product validation, software development, manufacturing and certification delivering high quality products and services to reduce complexity, speed up time to market, eliminate risk and reduce costs. The company has already designed, manufactured and shipped millions of IoT devices since its inception.
Ikotek, the only US-based global ODM with a pure IoT focus, combines end-to-end design consultancy across program management, R&D, sourcing, testing and production at its own as well as third party manufacturing facilities to produce designs for our customers. With a wide variety IoT projects in progress, such as asset tracking, dash cameras, PDAs and handhelds, point of sale (POS) devices and hardware for smart grid and metering deployments, Ikotek’s core focus is on the enterprise market as it looks to develop solutions to take full advantage of IoT at scale.
Led by Chief Executive Officer, Joe Peterson, who has more than 27 years of diverse experience across cellular and IoT industries in the US and international, Ikotek has gathered a team of industry veterans to amplify its vision of becoming the world’s most trusted IoT ODM. Recent additions to the US-based executive management team include:
Bill Leunis, the Vice President of Finance, who brings extensive experience in finance, operations and general management in manufacturing and EMS organizations. Previously, he has headed Finance in divisions of large multi-national corporations ranging in size from 500 to 20,000 people. In addition, he has served as CFO of a company, leading all aspects from its acquisition to IPO for eight years after going public.
Tim Newberg, the Vice President of Sales for the US and Canada, has joined with more than 25 years of experience and leadership in the wireless, broadband, consumer electronics and massive IoT industries. From hardware and software strategy to product marketing, sales and business development he has held senior executive positions at companies including Texas Instruments, Broadcom, Sequans, Rootmetrics, Polte and Sercomm.
Steve Burrington, the Head of North America Engineering, is a 25-year veteran of large and medium-sized wireless product development teams. Previously he served as Vice President of Engineering at CalAmp for the company’s telematics products. He has extensive experience of getting a diverse range of products to market, via organic development and JDM partnerships. In addition, he has held Vice President of Engineering roles at Netgear and Sierra Wireless.
These additions to the Ikotek management team have been supported by hires across the business and Ikotek now has more than 350 dedicated R&D employees and continues to add employees on a weekly basis.
“We’ve seen an incredible uptake of new customers over the last year and we’re excited to bring our unique ODM capabilities and advantages to customers,” said Peterson. “Supporting our customers with quick time-to-market, leading IoT industry expertise and cost-effective services and solutions is critical during a time where digital transformation is growing across all industries. To help manage growth, commercial excellence and new customers, I’m thrilled to welcome these three leading IoT and ODM capacities to our management team. We aim to serve our customers with local experts in North America and Europe and APAC so we can ensure that Ikotek is close to our customers and has local understanding of their needs.”
Ikotek targets mid-market IoT customers in response to increased demand for the design and build of products. The company’s ethos is to give customers a competitive advantage, through cost reductions and enable substantial savings to be achieved on their device design, manufacturing and certification costs. In addition, Ikotek is focused on taking customers’ projects from idea to market in record breaking time. In less than three months, Ikotek has provided end-to-end ODM services that took a complex IoT device to market including design, development and manufacturing.
“Ikotek exists to turn our customers’ device dreams into IoT reality,” Peterson added, pointing out the ways in which the company can help are listed on www.ikotek.com. “We’re keen to become customers’ indispensable partner in taking their innovations from concept to high volume product launches across global markets.”
About Ikotek
Ikotek is The IoT ODM. With a wide variety IoT projects currently underway, our core focus is on the enterprise market as it looks to develop solutions to take full advantage of IoT. We cover technologies from cellular connectivity, including NB-IoT and 5G, to satellite connections and from well-established IT to relative newcomers such as artificial intelligence IoT (AIoT).
For more information: www.ikotek.com LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928005870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom